Psyence Biomedical shares are trading higher after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.
$PBM
Biotechnology: Pharmaceutical Preparations
Health Care
Psyence Biomedical shares are trading higher after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.